Big changes are happening at Karyopharm Therapeutics Inc. (NASDAQ:KPTI), which makes the stock worth watching today. The company is among the top gainers of the stock market today, skyrocketing 3.03% or (0.5 points) to $17.17 from its previous close of $16.67. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 398113 contracts so far this session. KPTI shares had a relatively better volume day versus average trading capacity of 1.58 million shares, but with a 51.51 million float and a -2.26% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for KPTI stock indicates that the average analyst price target is $23.25 per share. This means the stock has a potential increase of 35.41% from where the KPTI share price has been trading recently which is between $16.63 and $17.2008. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $17. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $36.
During the recent trading session for Karyopharm Therapeutics Inc. (NASDAQ:KPTI), the company witnessed their stock rise $0.4 over a week and surge $2.97 from the price 20 days ago. When compared to their established 52-week high of $18.7, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 11/29/19. The recent low of $3.92 stood for a -8.18% since 01/03/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.55 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for KPTI is set at $23, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for Karyopharm Therapeutics Inc., the two-week RSI stands at 71.16. This figure suggests that KPTI stock, for now, is oversold, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current KPTI readings is similarly very revealing as it has a stochastic reading of 54.5% at this stage. This figure means that KPTI share price today is being neutral.
Technical chart claims that Karyopharm Therapeutics Inc. (KPTI) would settle between $17.03/share to $17.4/share level. However, if the stock price goes below the $16.46 mark, then the market for Karyopharm Therapeutics Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $16.26 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.13. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at JP Morgan raised their recommendation on shares of KPTI from Neutral to Overweight in their opinion released on July 23. Robert W. Baird analysts again handed out a Outperform recommendation to Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stock but they lifted target price for the shares in a flash note issued to investors on July 05. The target price has been raised from $15 to $25. Analysts at H.C. Wainwright are sticking to their Buy stance. However, on July 05, they lifted price target for these shares to $32 from $29.
KPTI equity has an average rating of 2.07, with the figure leaning towards a bullish end. 8 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 8 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 8 analysts rated Karyopharm Therapeutics Inc. (NASDAQ:KPTI) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Karyopharm Therapeutics Inc. (KPTI)’s current-quarter revenues are projected to climb by nearly 7497.1% to hit $15.65 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 26.4% from $30.34 million to a noteworthy $38.35 million. At the other end of the current quarter income statement, Karyopharm Therapeutics Inc. is expected to see its adjusted earnings surge by roughly 29.2% to hit $-0.68 per share. For the fiscal year, KPTI’s earnings are projected to climb by roughly -0.3% to hit $-3.15 per share.